Peri-implant Mucositis
Conditions
Brief summary
To test the modification of the implant prosthesis, in order to facilitate access to biofilm control, in combination with decontamination of the implant surface by means of an ultrasonic device with a plastic tip and plastic curettes, in comparison with the decontamination of the implant surface by means of an ultrasonic device with a plastic tip and plastic curettes, and no modification of the implant prosthesis.
Interventions
PROCEDUREModification of the implant supported prostheses in order to facilitate oral hygiene
Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
Sponsors
Universitat Internacional de Catalunya
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* (1) Presence of, at least, one titanium implant exhibiting peri-implant mucositis, defined as bleeding on gentle probing (0.15 N) in at least one peri-implant site. (2) No signs of loss of supporting bone after initial bone remodelling. In cases where baseline radiograph is available, it will be used for comparison, otherwise a maximum of 2 mm of crestal bone loss will be accepted (5). (3) Single tooth and bridgework restoration with an inappropriate prosthesis design or contour which difficult oral hygiene access (overcontoured prosthesis, prostheses presenting closed embrasures, an abrupt emergence profile or excessive buccal flanges). (4) Presence of \>1 mm of keratinized peri-implant mucosa. (5) A good level of oral hygiene, defined as an O'Leary et al. plaque index \<25% (16). (6) Absence of systemic diseases that could influence the outcome of the therapy (i.e. controlled diabetes, with HbA1c\<7, patients will be included). (7) Non-smoker or light smoking status in smokers (\<10 cigarettes/day).
Exclusion criteria
* (1) Untreated periodontal conditions. (2) Pregnant or lactating women. (3) Patients who received systemic antibiotics in the last 3 months. (4) Patients who received treatment of PM in the past 3 months. (5) Patients receiving corticoids or medications known to have effect on gingival growth i.e. calcium channel antagonists, immunosuppressants or antiepileptic drugs. In those cases diagnosed with peri-implantitis, individualized treatment will be provided, apart from the present study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate modified sulcus Bleeding Index changes at 3 and 6 months, by the modification of the implant prosthesis in order to facilitate oral hygiene, hygiene instructions and surface decontamination | 1, 3 and 6 months |
Countries
Spain
Contacts
Primary ContactBeatriz de Tapia
Outcome results
None listed